Krystal Biotech (NASDAQ:KRYS) Share Price Crosses Above 200-Day Moving Average – Here’s What Happened

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $310.10 and traded as high as $316.86. Krystal Biotech shares last traded at $315.34, with a volume of 345,860 shares traded.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on KRYS shares. Zacks Research downgraded shares of Krystal Biotech from a “hold” rating to a “strong sell” rating in a research note on Friday, October 23rd. Citigroup reduced their price target on Krystal Biotech from $416.00 to $412.00 and set a “buy” rating on the stock in a research report on Tuesday, November 3rd. Bank of America increased their price objective on Krystal Biotech from $392.00 to $400.00 and gave the company a “buy” rating in a report on Monday, September 21st. Royal Bank Of Canada lowered their price objective on Krystal Biotech from $400.00 to $375.00 and set an “outperform” rating for the company in a research report on Tuesday, November 3rd. Finally, The Goldman Sachs Group initiated coverage on Krystal Biotech in a research note on Thursday, September 24th. They set a “buy” rating and a $441.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $375.00.

Read Our Latest Analysis on Krystal Biotech

Krystal Biotech Trading Down 2.3%

The company has a market cap of $9.14 billion, a PE ratio of 40.42 and a beta of 0.56. The firm’s 50-day simple moving average is $322.48 and its two-hundred day simple moving average is $310.42.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.79 by $0.26. Krystal Biotech had a net margin of 47.91% and a return on equity of 17.02%. The business had revenue of $127.34 million during the quarter, compared to the consensus estimate of $125.77 million. As a group, analysts predict that Krystal Biotech, Inc. will post 7.74 EPS for the current year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the sale, the insider owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors have recently bought and sold shares of KRYS. Parallel Advisors LLC increased its stake in shares of Krystal Biotech by 2.0% in the third quarter. Parallel Advisors LLC now owns 1,733 shares of the company’s stock worth $576,000 after acquiring an additional 34 shares during the period. Signaturefd LLC boosted its holdings in Krystal Biotech by 27.3% in the third quarter. Signaturefd LLC now owns 168 shares of the company’s stock valued at $56,000 after purchasing an additional 36 shares during the last quarter. Hanseatic Management Services Inc. boosted its holdings in Krystal Biotech by 2.0% in the third quarter. Hanseatic Management Services Inc. now owns 3,183 shares of the company’s stock valued at $1,059,000 after purchasing an additional 63 shares during the last quarter. Heritage Family Offices LLP acquired a new stake in Krystal Biotech during the 3rd quarter worth about $25,000. Finally, Silvant Capital Management LLC acquired a new stake in Krystal Biotech during the 2nd quarter worth about $30,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

About Krystal Biotech

(Get Free Report)

Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.

See Also

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.